Mirati Therapeutics Company BD Opportunity Scan Report 2026: Pipeline, Deals, Partnering Shortlist, and Outreach Priorities
This Mirati Therapeutics Company BD Opportunity Scan Report was built with PatSnap Life Sciences MCP workflows. Company & Deal Intelligence MCP connects the organization pipeline, transaction precedents and financial-report signals; Current Awareness MCP adds recent-event context. The output is a partnering shortlist with owner, stage, evidence package, IP risk, deal precedent and outreach rationale. Explore the MCP servers used in this report.
Decision date: 21 July 2026. This is a screening memorandum for business-development prioritization, not legal, patent, medical or investment advice. “Not returned” means the searched MCP result did not supply the field and should not be read as evidence of absence.
Executive BD thesis
Mirati Therapeutics presents a practical BD-screening case because its returned pipeline contains 33 records and the deal search returned 7 transaction records. The lead returned asset is Adagrasib, associated with KRAS G12C and KRAS G12C mutant Non-small Cell Lung Cancer, Metastatic Non-Squamous Non-Small Cell Lung Carcinoma, KRAS G12C mutant Colorectal Cancer, at Approved. The immediate objective is not to price a transaction; it is to identify where a focused outreach can unlock regional development, indication expansion, platform access, combination strategy, manufacturing leverage or non-dilutive capital.
The scan prioritizes assets with a named development owner and a traceable stage, then applies a conservative IP screen. A high-quality first meeting should ask for the current clinical/regulatory package, ownership chain, third-party licenses, patent-family schedule, CMC readiness and the specific rights the company is prepared to discuss.
Partnering shortlist
| Priority | Asset / workstream | Owner | Stage | Evidence package | IP risk screen | Deal precedent | Outreach rationale |
|---|---|---|---|---|---|---|---|
| 1 | Adagrasib | Mirati Therapeutics, Inc. | Approved | Pipeline record: KRAS G12C; KRAS G12C mutant Non-small Cell Lung Cancer, Metastatic Non-Squamous Non-Small Cell Lung Carcinoma, KRAS G12C mutant Colorectal Cancer. Confirm CMC, regulatory history, trial registry and data room. | Medium screening risk. Verify composition-of-matter, method-of-use, formulation/delivery claims, platform encumbrances, territory coverage and freedom to operate. | Mirati/Bristol Myers Squibb and Aadi mutually agreed to terminate their collaboration and clinical supply agreement | Approved asset with KRAS G12C exposure; explore regional rights, co-development, option-to-license or financing-linked structures. |
| 2 | Nivolumab | Mirati Therapeutics, Inc. | Phase 3 | Pipeline record: PD-1; Advanced Lung Non-Small Cell Squamous Carcinoma, Metastatic Non-Squamous Non-Small Cell Lung Carcinoma, Locally Advanced Clear Cell Renal Cell Carcinoma. Confirm CMC, regulatory history, trial registry and data room. | Medium screening risk. Verify composition-of-matter, method-of-use, formulation/delivery claims, platform encumbrances, territory coverage and freedom to operate. | Bristol Myers Squibb Completes Acquisition of Mirati Therapeutics, Strengthening and Diversifying Oncology Portfolio | Phase 3 asset with PD-1 exposure; explore regional rights, co-development, option-to-license or financing-linked structures. |
| 3 | Cetuximab | Mirati Therapeutics, Inc. | Phase 3 | Pipeline record: EGFR; KRAS G12C mutant Colorectal Cancer. Confirm CMC, regulatory history, trial registry and data room. | Medium screening risk. Verify composition-of-matter, method-of-use, formulation/delivery claims, platform encumbrances, territory coverage and freedom to operate. | Zai Lab collaborates with Mirati Therapeutics to develop and commercialize adagrasib for cancer treatment in Greater China. | Phase 3 asset with EGFR exposure; explore regional rights, co-development, option-to-license or financing-linked structures. |
| 4 | Sitravatinib | Mirati Therapeutics, Inc. | Phase 3 | Pipeline record: AXL x RET x Tie-2 x VEGFR1 x VEGFR2 x VEGFR3 x c-Met; Advanced Lung Non-Small Cell Squamous Carcinoma, Metastatic Non-Squamous Non-Small Cell Lung Carcinoma, Recurrent Endometrial Cancer. Confirm CMC, regulatory history, trial registry and data room. | Medium screening risk. Verify composition-of-matter, method-of-use, formulation/delivery claims, platform encumbrances, territory coverage and freedom to operate. | Mirati/Bristol Myers Squibb and Aadi mutually agreed to terminate their collaboration and clinical supply agreement | Phase 3 asset with AXL x RET x Tie-2 x VEGFR1 x VEGFR2 x VEGFR3 x c-Met exposure; explore regional rights, co-development, option-to-license or financing-linked structures. |
| 5 | Palbociclib | Mirati Therapeutics, Inc. | Phase 1 | Pipeline record: CDK4 x CDK6; Advanced Malignant Solid Neoplasm. Confirm CMC, regulatory history, trial registry and data room. | Medium screening risk. Verify composition-of-matter, method-of-use, formulation/delivery claims, platform encumbrances, territory coverage and freedom to operate. | Bristol Myers Squibb Completes Acquisition of Mirati Therapeutics, Strengthening and Diversifying Oncology Portfolio | Phase 1 asset with CDK4 x CDK6 exposure; explore regional rights, co-development, option-to-license or financing-linked structures. |
Shortlist interpretation. The top row should receive the fastest outreach, subject to confirmation that the returned owner and development stage remain current. Rows two through five are option-value workstreams: they can support a regional license, co-development, research collaboration, asset carve-out or structured option if the evidence package is sufficiently differentiated.
Pipeline and evidence-package readout
The organization pipeline fetch anchors asset identity, target, indication and development stage. Those fields should be reconciled against the sponsor’s current presentation, trial registry, regulatory correspondence and data-room index. For each shortlisted asset, request protocol history, enrollment and discontinuation data, endpoint definitions, biomarker strategy, safety narratives, manufacturing comparability and the latest investigator or regulator feedback.
Evidence quality is strongest when asset identity, stage, owner and indication are mutually consistent across sources. A mismatch is itself a BD signal: it may reflect a recent transfer, dormant program, territory split, combination strategy or portfolio reprioritization. Any mismatch should be resolved before valuation or term-sheet design.
Deal precedents and structure signals
| Date | Transaction | Status | Disclosed economics |
|---|---|---|---|
| 2024-05-08 | Mirati/Bristol Myers Squibb and Aadi mutually agreed to terminate their collaboration and clinical supply agreement | Terminated | disclosed: false |
| 2023-10-08 | Bristol Myers Squibb Completes Acquisition of Mirati Therapeutics, Strengthening and Diversifying Oncology Portfolio | Completed | total_amount: 4800; disclosed: false |
| 2021-05-28 | Zai Lab collaborates with Mirati Therapeutics to develop and commercialize adagrasib for cancer treatment in Greater China. | Active | upfront_payment: 65; milestone_payment: 273; total_amount: 338; disclosed: true |
The most relevant returned precedent is: Mirati/Bristol Myers Squibb and Aadi mutually agreed to terminate their collaboration and clinical supply agreement (2024-05-08). Precedents should guide structure rather than mechanically determine price. Normalize for development stage, territory, modality, included indications, opt-in rights, cost sharing, manufacturing obligations, royalties, milestones and change-of-control provisions. Where economics are undisclosed, the precedent still informs counterparties, strategic intent and preferred transaction form.
Financial capacity and partnering pressure
- Mirati Therapeutics, Inc. - 2021 Quarterly report: Mirati Therapeutics, Inc. - 2021 Quarterly report 7. License and Collaboration Agreements Royalties. As the license is deemed to be the predominant item to which sales-based royalties relate, the Company will recognize revenue when the related sales occur. No royalty revenue was recognized during the three and nine months ended September 30, 2021 or 2020. Pfizer Agreement In October 2014, the Company entered into a drug discovery collaboration and option agreement with Array BioPharma, Inc. (“Array,” acquired by Pfizer Inc. (“Pfizer”) in July 2019) whereby Array provided services to facilitate the discovery, optimization and development of small molecule compounds that bind and specifically inhibit KRAS G12C. In June 2017, the two parties entered into a second, separate discovery collabora
- Mirati Therapeutics, Inc. - 2021 Annual report: Mirati Therapeutics, Inc. - 2021 Annual report 5. Other Current Assets and Other Long-Term Assets In October 2014, the Company entered into a drug discovery collaboration and option agreement with Array BioPharma, Inc. (“Array,” acquired by Pfizer Inc. (“Pfizer”) during 2019) whereby Array provided services to facilitate the discovery, optimization and development of small molecule compounds that bind and specifically inhibit KRAS G12C. In June 2017, the two parties entered into a second, separate discovery collaboration and option agreement whereby Array provided services to facilitate the discovery, optimization and development of small molecule compounds that bind and specifically inhibit KRAS G12D. Both agreements established an option mechanism which enabled the Company to elect an ex
Financial signals influence timing and leverage. Cash runway, operating burn, committed trial spend, debt covenants, shelf capacity and recent financings determine whether Mirati Therapeutics is more likely to pursue a broad license, regional partnership, cost-sharing collaboration, royalty financing or asset-level option. Figures returned from filings should be rechecked in the latest report before any negotiation.
Recent events and outreach timing
- No company-specific recent-news passage was returned. Confirm the latest clinical, regulatory, financing and leadership events directly with management.
Recent clinical, regulatory, financing, leadership and portfolio events can create a narrow outreach window. The BD team should map each event to a decision owner, an asset-level question and a proposed structure. Avoid generic “partnership interest” messages; lead with the specific program, territory, capability gap and evidence package that the prospective partner can improve.
IP and diligence risk screen
The default IP flag is medium until verified. Review composition-of-matter and sequence claims, method-of-use coverage, formulation and delivery patents, manufacturing know-how, platform licenses, university or government rights, prosecution status, patent-term adjustment/extension, oppositions, litigation, inventorship and freedom to operate. For biologics, cell/gene therapies and platform technologies, background IP and improvement-right provisions can be as important as the asset patents.
Commercial diligence should test addressable population, diagnosis and referral pathway, standard of care, competitor readouts, endpoint sensitivity, payer evidence needs, launch infrastructure and territory-specific regulatory requirements. The value of an asset is a function of the complete evidence package and executable rights—not development stage alone.
Recommended outreach sequence
- Contact the asset-level BD owner with a one-page rationale linked to the lead program and proposed territory or capability contribution.
- Request a non-confidential package covering current stage, dataset maturity, ownership, patent schedule, CMC status and partnering perimeter.
- Benchmark the returned precedents using stage-, modality- and territory-adjusted structures.
- Advance only programs with a coherent owner, evidence package, IP path and decision timeline into confidential diligence.
- Set explicit stop/go gates for data quality, freedom to operate, financing capacity and strategic fit.
Bottom line
Mirati Therapeutics merits targeted BD outreach where the returned pipeline and evidence package align with a partner’s geography, development capability or commercial infrastructure. The recommended next action is to validate Adagrasib, confirm rights availability and test a structure calibrated to the company’s financial position and precedent set. The shortlist is designed to turn fragmented intelligence into an actionable owner-by-owner outreach plan.
Explore PatSnap Open Platform MCP Servers and build your next biopharma BD workflow.
